Regulus Therapeutics (RGLS) Reports In-Line Q2 EPS

Regulus Therapeutics (NASDAQ: RGLS) reported Q2 EPS of ($0.08), in-line with the analyst estimate of ($0.08).

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• Arxis, Inc. (ARXS) Reports Q2 EPS of $0.28; offers guidance
• Plexus Corp (PLXS) Tops Q3 EPS by 19c ; Offers Guidance
• Waystar Holding Corp. (WAY) Reports Q2 EPS of $0.43 ; Offers Guidance